Uncategorized
Chairman delivers year’s industry highlights at OIS
LAS VEGAS — This year has been an innovative year in ophthalmology with several milestones being reached, including a number of FDA submissions and successful phase 3 clinical trials, according to Emmett T. Cunningham Jr., MD, PhD, MPH, who gave the “Chairman’s 2015 Year in Review” at the Ophthalmology Innovation Summit here. Spark Therapeutics reported clinical results for RPE-65, the first phase 3 clinical trial for gene therapy for the eye. AbbVie also reported positive phase 3 trial results for Humira (adalimumab) for treatment of noninfectious uveitis.